Test Price
2,800 AED✅ Home Collection Available
ALG11 Gene Congenital Disorder of Glycosylation Type Ip (CDG‑Ip) Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary: Precision genetic analysis for ALG11-related congenital disorder of glycosylation type Ip (CDG‑Ip) via targeted next-generation sequencing (NGS), delivering 99.9% diagnostic sensitivity at our ISO 9001:2015-accredited facility in Dubai Healthcare City. The test supports early diagnosis and metabolic management for affected families. Includes VIP mobile phlebotomy and temperature-controlled cold-chain home collection, telephonic post-test clinical guidance, and direct insurance billing verification via WhatsApp.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- Price: 2,800 AED.
- Turnaround Time: 3–4 Weeks.
Test Overview & Methodology
This test identifies pathogenic variants in the ALG11 gene responsible for congenital disorder of glycosylation type Ip (CDG‑Ip), a rare inherited multisystem metabolic disorder. Performed on whole blood or extracted DNA, our UAE laboratory uses gold-standard targeted NGS technology, ensuring high-depth coverage of all coding exons and flanking intronic regions. Results are interpreted by DHA-licensed clinical geneticists and reported with clear variant classification per ACMG guidelines. Early molecular confirmation enables proactive metabolic support, genetic counselling, and family screening.
The assay is validated for germline variant detection and includes orthogonal confirmation of clinically significant findings. Turnaround time is 3 to 4 weeks from sample receipt. Specimens are processed under strict chain-of-custody protocols with full traceability.
| Feature | Our ALG11 Targeted NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity for ALG11 mutations | ~95% coverage; may miss deep intronic variants |
| Method | Targeted NGS (Next-Generation Sequencing) | Whole Exome Sequencing (WES) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Cost Efficiency | 2,800 AED (targeted, clinically focused) | Higher cost; broader scope with incidental findings |
Physician Insight & Safety Protocols
“ALG11-CDG is a clinically heterogeneous condition that can present with variable neurological, hepatic, and coagulation abnormalities. This genetic result must always be interpreted alongside biochemical glycosylation profiles, clinical phenotype, and a detailed family history. Early molecular diagnosis facilitates tailored metabolic interventions and empowers families with accurate recurrence risk information.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Clinical Guidance
Always consult your treating physician before making any changes to prescribed therapies. Genetic testing is a diagnostic adjunct and does not replace ongoing clinical monitoring or medication management. If acute metabolic symptoms occur, prioritise emergency medical attention and defer sample collection until the patient is stable.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent – for individuals under 18 years, legal guardian consent is mandatory per UAE regulatory requirements; active acute illness that precludes safe phlebotomy (e.g., severe anaemia, uncompensated coagulopathy) requires physician clearance prior to collection.
- Red Flags – Seek Emergency Care Immediately: If the patient develops acute metabolic decompensation (seizures, intractable vomiting, lethargy, hypoglycaemia, unexplained bleeding), do not postpone emergency stabilisation for this test. Genetic analysis is elective; clinical urgency overrides scheduled collection.
- Pregnancy is not a contraindication, but pre-test genetic counselling is strongly advised to discuss potential implications for prenatal diagnosis.
Patient FAQ & Clinical Guidance
1. What is the ALG11 gene congenital disorder of glycosylation type Ip test?
This advanced genetic test screens the ALG11 gene for mutations causing congenital disorder of glycosylation type Ip (CDG‑Ip), a rare inherited metabolic condition. It is typically ordered when clinical signs such as developmental delay, coagulation abnormalities, liver dysfunction, or multisystem involvement suggest a CDG spectrum disorder. The test requires only a standard whole blood sample or extracted DNA and is performed using targeted next-generation sequencing for high diagnostic yield.
2. Is home sample collection available in the UAE for this test?
Yes, we offer VIP mobile phlebotomy and temperature-controlled cold-chain home collection across all Emirates, available daily from 8 AM to 11 PM. Our trained phlebotomists use paediatric-friendly techniques and validated collection tubes to ensure sample integrity from your doorstep to our laboratory. This service is safe, convenient, and ideal for families with limited mobility or busy schedules.
3. How long do results take and will a genetic counsellor explain them?
Results are typically ready within 3 to 4 weeks from sample receipt. A DHA-licensed clinical geneticist provides a telephonic post-test consultation to interpret the findings, covering variant significance, recurrence risk, and recommended follow-up. This ensures you fully understand the clinical implications before sharing the report with your primary physician.
4. What does the test price include and are there any additional fees?
The total price of 2,800 AED covers the full molecular analysis, bioinformatics interpretation, clinical report with ACMG classification, and the telephonic genetic counselling session. Home collection phlebotomy may incur a separate logistics fee depending on your Emirates and time of booking. Direct billing verification with your insurer is available via WhatsApp.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This test is performed in full accordance with UAE healthcare regulations. All genetic data handling adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143. Sample collection, transport, and storage comply with UAE Ministry of Health and Prevention standards for genetic testing.
Clinical & Logistical Metadata
| Test Name | ALG11 Gene Congenital Disorder of Glycosylation Type Ip (CDG‑Ip) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Extracted DNA |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | E77.8, Z13.228, Z84.81 |
| LOINC Code | 94068-7 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians